Claims
- 1. A compound of formula (I): ##STR77## in which: l is an integer of from 2 to 4;
- A and B are independently selected from the group consisting of oxygen atoms and sulfur atoms;
- one of R.sup.1 and R.sup.2 represents a group of formula (II): ##STR78## in which R.sup.3 is R.sub.f.sup.3 wherein R.sub.F.sup.3 represents an alkyl group containing from 10 to 22 carbon atoms, and
- R.sup.5 represents a hydrogen atom,
- and the other of R.sup.1 and R.sup.2 represents a group of (II.sub.f): ##STR79## wherein n.sub.f is an integer of from 2 to 10;
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.6 alkyl groups, or R.sub.f.sup.4 and R.sub.f.sup.5 or R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, form a heterocyclic ring which may be aromatic or partly or wholly saturated;
- said heterocyclic groups in formula (II.sub.f) having from 3 to 10 ring atoms, of which from 1 to 4 atoms are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of these being a nitrogen atom, and said heterocyclic group being unsubstituted or having at least one substituent selected from the group consisting of substituents (c):
- substituents (c):
- C.sub.1 -C.sub.6 alkyl groups, C.sub.1 -C.sub.5 hydroxyalkyl groups, C.sub.1 -C.sub.6 alkoxy groups, carbamoyl groups, mono- and di-alkylcarbamoyl groups in which the or each alkyl part is C.sub.1 -C.sub.5 and halogen atoms; or a pharmaceutically acceptable salt or ester thereof.
- 2. A compound as claimed in claim 1, wherein said compound has the formula (I) as shown in claim 1 in which R.sup.1 represents a group of formula (II.sub.f).
- 3. A compound as claimed in claim 1, wherein n.sub.f is 2 or 3.
- 4. A compound as claimed in claim 1, wherein l is 2 or 3.
- 5. A compound as claimed in claim 1, wherein n.sub.f is an integer from 2 to 6.
- 6. A compound as claimed in claim 1, wherein R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.6 alkyl groups.
- 7. A compound as claimed in claim 1, wherein R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group.
- 8. A compound as claimed in claim 1, wherein R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 10 ring atoms, said heterocyclic group bein unsubstituted or having at least one substitutent selected from the group consisting of C.sub.1 -C.sub.4 alkyl groups, C.sub.1 -C.sub.5 alkoxy groups, C.sub.1 -C.sub.5 hydroxyalkyl groups, carbamoyl groups and halogen atoms.
- 9. A compound as claimed in claim 1, wherein R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 and R.sup.2 represents said group of formula (II.sub.f).
- 10. A compound as claimed in claim 1, wherein R.sub.f.sup.3 represents an alkyl group having from 16 to 18 carbon atoms.
- 11. A compound as claimed in claim 1, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.6 alkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 12. A compound as claimed in claim 1, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 13. A compound as claimed in claim 1, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 10 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups, C.sub.1 -C.sub.5 alkoxy groups, C.sub.1 -C.sub.5 hydroxyalkyl groups, carbamoyl groups and halogen atoms;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 14. A compound as claimed in claim 1, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of C.sub.1 -C.sub.6 alkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 15. A compound as claimed in claim 1, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 16. A compound as claimed in claim 1, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 7 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 17. A compound as claimed in claim 1, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f .sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a piperidino or 1-pyrrolidinyl group, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 18. A compound as claimed in claim 1, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent a 1-pyridyl or 1-thiazolyl group which is unsubstituted or has at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 19. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR80## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 20. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR81## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 21. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR82## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 22. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR83## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 23. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR84## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 24. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR85## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 25. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR86## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 26. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR87## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 27. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR88## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 28. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR89## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 29. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR90## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 30. A compound as claimed in claim 1, selected from the group consisting of the compound of formula: ##STR91## its mirror image and pharmaceutically acceptable salts of said compound and of its mirror image.
- 31. A pharmaceutical composition for the treatment of inflammation or shock, comprising an effective amount of a PAF antagonist in combination with a pharmaceutically acceptable carrier or diluent, wherein the PAF antagonist is selected from the group consisting of compounds of claim 1.
- 32. A composition as claimed in claim 31, wherein said compound has the formula (I) as shown in claim 31 in which R.sup.1 represents a group of formula (II.sub.f).
- 33. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.6 alkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 34. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f):
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 35. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 10 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups. C.sub.1 -C.sub.5 alkoxy groups, C.sub.1 -C.sub.5 hydroxyalkyl groups, carbamoyl groups and halogen atoms;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 36. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of C.sub.1 -C.sub.6 alkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 37. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 38. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 7 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 39. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a piperidino or 1-pyrrolidinyl group, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 40. A pharmaceutical composition as claimed in claim 31, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent a 1-pyridyl or 1-thiazolyl group which is unsubstituted or has at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 41. A method for the treatment of prophylaxis of asthma, inflammation or shock comprising administering an amount of a PAF antagonist to an animal sufficient to effect treatment or prophylaxis of inflammation or shock, wherein said PAF antagonist is selected from the group consisting of compounds of claim 1.
- 42. A method as claimed in claim 41, wherein said compound has the formula (I) as shown in claim 41 in which R.sup.1 represents a group of formula (II.sub.f).
- 43. A method as claimed in claim 41, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of hydrogen atoms and C.sub.1 -C.sub.6 alkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 44. A method as claimed in claim 41, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 45. A method as claimed in claim 41, wherein:
- R.sup.1 represents said group of formula --CONHR.sub.f.sup.3 ;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 10 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups, C.sub.1 -C.sub.5 alkoxy groups, C.sub.1 -C.sub.5 hydroxyalkyl groups, carbamoyl groups and halogen atoms;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 46. A method as claimed in claim 41, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6 are independently selected from the group consisting of C.sub.1 -C.sub.6 alkyl group
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 47. A method as claimed in claim 41, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a non-aromatic heterocyclic group having from 5 to 7 ring atoms, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 48. A method as claimed in claim 41, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent an aromatic heterocyclic group having from 5 to 7 ring atoms, said group being unsubstituted or having at least one substituent selected from the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 49. A method as claimed in claim 41, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f)
- R.sub.f.sup.4 and R.sub.f.sup.5, together with the nitrogen atom to which they are attached, represent a piperidino or 1-pyrrolidinyl group, and R.sub.f.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 50. A method as claimed in claim 41, wherein:
- R.sup.1 represents a group of formula --CONHR.sub.f.sup.3, where R.sub.f.sup.3 represents a C.sub.16 -C.sub.18 alkyl group;
- R.sup.2 represents said group of formula (II.sub.f);
- R.sub.f.sup.4, R.sub.f.sup.5 and R.sub.f.sup.6, together with the nitrogen atom to which they are attached, represent a 1-pyridyl or 1-thiazolyl group which is unsubstituted or has at least one substituent selected form the group consisting of C.sub.1 -C.sub.5 alkyl groups and C.sub.1 -C.sub.5 hydroxyalkyl groups;
- n.sub.f is an integer from 2 to 6; and
- l is 2 or 3.
- 51. A method as claimed in claim 41 wherein said compound has the formula ##STR92##
Priority Claims (3)
Number |
Date |
Country |
Kind |
60-163965 |
Jul 1985 |
JPX |
|
61-157319 |
Jul 1986 |
JPX |
|
62-15484 |
Jan 1987 |
JPX |
|
Parent Case Info
This application is a continuation-in-part of (i) application Ser. No. 69,041 filed July 1, 1987 (now abandoned) and of (ii) application Ser. No. 147,081 filed Jan. 20, 1988 (now abandoned) which was a continuation application of Ser. No. 888,155 filed July 18, 1986 (now abandoned).
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4794183 |
Nakamura et al. |
Dec 1988 |
|
Related Publications (1)
|
Number |
Date |
Country |
|
147081 |
Jan 1988 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
888155 |
Jul 1986 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
69041 |
Jul 1987 |
|